Bedikian A Y, Plager C, Papadopoulos N, Ellerhorst J, Smith T, Benjamin R S
The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Oncol Rep. 2000 Jul-Aug;7(4):883-6. doi: 10.3892/or.7.4.883.
A phase II study was undertaken to determine the efficacy of Bexarotene in melanoma. Between November 1997 and April 1998, 19 patients were given Bexarotene in single daily oral doses of 450 mg/m2 in capsule form continuously. Nineteen patients, four with choroidal metastatic melanoma, were treated. No responses were seen. Five patients had stable disease, two of the four with choroidal melanoma, had tumor progression. Myelosuppression was mild. Grade 3 myalgia, asthenia, diarrhea, cold hands/feet, and mood changes were seen in one patient each. Changes in serum triglyceride and thyroxine levels were common. Bexarotene, as used in this study, is not effective against melanoma.
开展了一项II期研究以确定贝沙罗汀治疗黑色素瘤的疗效。1997年11月至1998年4月期间，19例患者连续每日口服胶囊形式的贝沙罗汀，剂量为450mg/m²。对19例患者进行了治疗，其中4例为脉络膜转移性黑色素瘤。未观察到缓解情况。5例患者病情稳定，4例脉络膜黑色素瘤患者中有2例出现肿瘤进展。骨髓抑制较轻。1例患者出现3级肌痛、乏力、腹泻、手足冰凉和情绪变化。血清甘油三酯和甲状腺素水平变化较为常见。本研究中使用的贝沙罗汀对黑色素瘤无效。
